Discovery of the sixth *Candida auris* clade in Singapore

- Chayaporn Suphavilai¹, Karrie Kwan Ki Ko^{1,2,3,4,5}, Kar Mun Lim, Mei Gie Tan, Patipan
- Boonsimma¹, Joash Jun Keat Chu¹, Sui Sin Goh², Prevena Rajandran², Lai Chee Lee⁶, Kwee 4
- Yuen Tan⁶, Bushra Binte Shaik Ismail⁶, May Kyawt Aung⁶, Yong Yang^{4,6}, Jean Xiang Ying 5
- Sim^{4,6,7}, Indumathi Venkatachalam^{4,6,7}, Benjamin Pei Zhi Cherng^{4,7}, Bram Spruijtenburg^{8,9}, Kian Sing Chan^{3,4}, Lynette Lin Ean Oon^{3,4}, Ai Ling Tan^{2,4}, Yen Ee Tan^{2,4}, Limin Wijaya^{4,7}, Ban Hock 6
- 7
- Tan^{4,7}, Moi Lin Ling^{4,6}, Tse Hsien Koh^{2,4}, Jacques F. Meis^{8,9,10}, Clement Kin Ming Tsui^{11,12,13}, Niranjan Nagarajan*^{1,5} 8
- 9

1 2

3

10 11

12

13 14

15

16

17 18

19

20

21

22

23

24

25

26

27 28

29

30

31 32

- ^Contributed equally to this work
- *Corresponding authors
 - 1. Genome Institute of Singapore, Agency for Science, Technology and Research (A*STAR), Singapore
 - 2. Department of Microbiology, Singapore General Hospital, Singapore
 - 3. Department of Molecular Pathology, Singapore General Hospital, Singapore
 - 4. Duke-NUS Medical School, Singapore
 - 5. Yong Loo Lin School of Medicine, National University of Singapore, Singapore
 - 6. Department of Infection Prevention and Epidemiology, Singapore General Hospital, Singapore
 - Department of Infectious Diseases, Singapore General Hospital, Singapore
 - 8. Department of Medical Microbiology and Infectious Diseases, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands
 - Center of Expertise in Mycology Radboud University Medical Center/Canisius-Wilhelmina Hospital, 6532 SZ Nijmegen, The Netherlands
 - 10. Department I of Internal Medicine. University Hospital Cologne. Excellence Center for Medical Mycology, Cologne, Germany
 - 11. Infectious Diseases Research Laboratory, National Centre for Infectious Diseases, Tan Tock Seng Hospital, Singapore
 - 12. Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore
 - 13. Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada

Summary 33

- 34 Background
- 35 The emerging fungal pathogen Candida auris poses a serious threat to global public health due
- 36 to its worldwide distribution, multidrug-resistance, high transmissibility, propensity to cause
- 37 outbreaks and high mortality rates. We report three *C. auris* isolates detected in Singapore,
- which are genetically distinct from all known clades (I-V) and represent a new clade (Clade VI). 38
- 39 Methods
- 40 Three epidemiologically unlinked clinical isolates belonging to the potential new C. auris clade
- 41 were whole-genome sequenced and phenotypically characterized. The complete genomes of
- 42 these isolates were compared to representative genomes of all known clades. To provide a
- 43 global context, 3,651 international whole-genome sequences (WGS) from the NCBI database
- 44 were included in the high-resolution single nucleotide polymorphism (SNP) analysis. Antifungal

- 45 resistance genes, mating type locus, and chromosomal rearrangements were characterized
- 46 from the WGS data of the Clade VI isolates. We further implemented Bayesian logistic
- 47 regression models to simulate the automatic detection of Clade V and VI as their WGS data
- 48 became available.
- 49 Findings
- The three Clade VI isolates were separated by >36,000 SNPs from all existing *C. auris* clades.
- 51 These isolates had opposite mating type allele and different chromosomal rearrangements
- 52 when compared to their closest Clade IV relatives. As a proof-of-concept, our classification
- 53 model was able to flag these outlier genomes as a potential new clade. Furthermore, an
- 54 independent WGS submission from Bangladesh was found to belong to this new clade.
- 55 Interpretation
- The discovery of a new *C. auris* clade in Singapore and Bangladesh, showing close relationship
- to Clade IV members in South America, highlights the unknown genetic diversity and origin of *C*.
- 58 auris, particularly in under-resourced regions. Active surveillance in clinical settings, along with
- effective sequencing strategies and downstream analysis, will be essential in the identification of
- 60 novel strains, tracking of transmission, and containment of adverse clinical impacts caused by
- 61 C. auris infections.
- 62 Funding
- This work was supported by the Singapore National Medical Research Council (NMRC)
- research training fellowship (MOH-FLWSHP19may-0005), the NCRS Duke-NUS Academic
- 65 Medical Center Academic Clinical Program grant (09/FY2022/P1/17-A32, GRDUKP003401),
- and the Genedant-GIS Innovation Program grant.

67 Research in context

- 68 Evidence before this study
- We searched PubMed using the search terms "Candida auris" AND "clade", for papers
- 70 published between Jan 1, 2009, and July 1, 2023. This search retrieved 115 publications. 60
- 71 relevant publications were identified. 28 studies analyzed and discussed the molecular
- 72 epidemiology of *C. auris*, including the description of *C. auris* clades, either in outbreak or
- 73 surveillance settings. There were 11 case reports of *C. auris* clinical cases that included clade
- 74 determination. Two studies focused on the detection and clade determination of *C. auris* from
- 75 non-healthcare environments. Clade-specific characteristics were described or analyzed in 14
- studies. One study applied machine learning to *C. auris* drug resistance analysis, but not for
- 77 clade determination. Four studies focused on the description of potentially new *C. auris*
- 78 lineages, subclades, or clades. All publications described isolates that belong to one of the five
- 79 known C. auris clades (I-V). All publications found that strains from different clades differed by
- 80 more than 35,000 SNPs, and that there are clade-specific differences in geographical
- distribution, phenotypic characteristics, antifungal susceptibility profile, outbreak potential, and
- 82 clinical manifestations.

83

- The NCBI Pathogen Detection system contained 4,506 *C. auris* genomes on July 1, 2023.
- 85 There were ten (0.22%) submissions from Southeast Asian countries and 92 (2.04%)

- submissions from South Asia and the Indian subcontinent, which are parts of the Indomalayan
- 87 biogeographic realm.
- 88 Added value of this study
- 89 To the best of our knowledge, we are the first group to perform hybrid assemblies on three
- 90 representative isolates in a new *C. auris* clade, which is separated from all other existing clades
- 91 (I-V) by >36,000 SNPs. Whole-genome SNP analysis and phenotypic characterization of these
- 92 epidemiologically unlinked isolates detected in Singapore suggest that they represent a
- 93 previously unreported sixth major clade. High-resolution SNP analysis of 3,651 international
- 94 whole-genome sequences from the NCBI database, which generated the final dataset
- 95 consisting of more than 6.6 million genome pairs, revealed six distinct genetic clusters
- 96 representing the five known clades and the new sixth clade (Indomalayan). In addition, we
- 97 demonstrate that a machine learning approach can be used to flag these outlier genomes for
- 98 further investigations as soon as they become available, thus providing the earliest possible
- 99 alert for potential new public health threats.
- 100 Implications of all the available evidence
- 101 Despite the high antimicrobial resistance burden in Southeast Asia and South Asia, these
- regions are disproportionately underrepresented in terms of genomic surveillance of *C. auris*, a
- multidrug-resistant fungal pathogen. The detection of three epidemiologically unlinked *C. auris*
- isolates in Singapore belonging to a new *C. auris* clade suggests that yet-to-be-reported strains
- may be circulating in the region. Given the propensity for multidrug resistance, healthcare-
- associated infection outbreaks, and the associated high mortality, active surveillance and
- 107 continued vigilance is necessary.

Introduction

108

119

126

- 109 Candida auris is an emerging multidrug-resistant (MDR) fungal pathogen that has been
- implicated in a large number of healthcare-associated infection outbreaks^{1–8}. Invasive infections
- 111 caused by MDR *C. auris* are associated with high mortality rates in vulnerable patient groups²⁻
- 112 ¹⁰. Within healthcare settings, *C. auris* appears to be highly transmissible and is known to
- persist in the environment^{4-6,11}. Given its worldwide distribution, MDR characteristics, high
- transmissibility, and high mortality rates, *C. auris* represents a serious threat to global public
- health. The World Health Organization highlighted this threat by classifying *C. auris* as a 'critical
- priority' pathogen last year¹², while the U.S. Centers for Disease Control and Prevention
- declared *C. auris* as an 'urgent' antimicrobial resistance threat' 13, further emphasizing the need
- to understand and mitigate this public health threat.
- Five geographically distinct *C. auris* clades have been described to date. This includes Clade I
- 121 (South Asian), Clade II (East Asian), Clade III (African), Clade IV (South American), and Clade
- 122 V (Iranian)^{10,14–16}. These clades were recognized based on whole-genome sequence analyses,
- where strains from different clades differed by more than 35,000 single nucleotide
- polymorphisms (SNPs)^{14,17}. Furthermore, these clades differed in terms of their antifungal
- susceptibility profiles, outbreak potential, and clinical manifestations^{18–20}.
- Here we report three epidemiologically unlinked *C. auris* isolates detected in Singapore, which
- appear to represent members of a new clade. The index isolate (A) was first detected by
- polymerase chain reaction (PCR) from a routine *C. auris* screening swab and subsequently

cultured in April 2023. WGS analysis of isolate A showed that the strain was separated from all known clades by more than 36,000 SNPs. Retrospective analysis of our laboratory's archived *C. auris* isolates subsequently discovered two additional isolates (B and C) with similar genomic and phenotypic characteristics. Isolate C was previously short-read sequenced and reported in 2019 (SRR10102336)²¹.

To understand the global context, we analyzed 3,651 C. auris whole-genome sequences in the NCBI database together with the sequence data generated in this study. The final dataset consisted of >6.6 million genome pairs, and six distinct genetic clusters were recognized, consisting of the five known clades and the new Indomalayan clade. From the NCBI database, we identified one additional independently submitted genome from Bangladesh (SRR24877249), which belongs to this new clade. The previously submitted WGS data of isolate C from Singapore (SRR10102336)²¹, and the independent upload from Bangladesh (SRR24877249) were neither identified nor reported as representatives of a potential new clade at the time of writing. The presence of potentially novel, but unrecognized genome data present in the NCBI database demonstrates a gap in novel pathogen or genotype detection despite the availability and accessibility of genomic surveillance data. Given the vast body of microbial genomic data available in the post-COVID-19 pandemic era, it is evident that the challenge lies not only in data availability but also in the ability to fully exploit the data for timely public health alerts and decision-making. To address this gap, we implemented a machine learning approach to demonstrate that potentially novel genomes can be flagged automatically for further investigations, as soon as the genome data become available.

This study reports the hybrid assemblies, genomic analysis, and phenotypic characteristics of three representatives of the sixth *C. auris* clade. We further simulated the automatic detection of the new clade, demonstrating that microbial genomic surveillance can be further augmented to provide early alerts for potential emergent threats.

Methods

130

131

132

133

134 135 136

137

138

139

140

141

142

143 144

145

146

147

148

149

150

151

152153

154

155

156

157

166

- 158 Candida auris microbiological and epidemiological analysis
- 159 Three *C. auris* isolates from three epidemiologically unlinked patients in Singapore were
- included in this study. The full description of the isolates is summarized in appendix 1 (p3).
- Details of phenotypic identification and antifungal susceptibility testing are in appendix 1 (p4).
- 162 Four ATCC C. auris isolates from Clade I-IV were included as clade-specific controls in this
- study (appendix 2). The sample and patient identifiers used throughout the manuscript have
- been modified from the original identifiers, and the identifiers used in the manuscript and
- supplementary materials cannot reveal the identity of the subjects.
- 167 This study used pre-existing retrospective collections of isolates and our analyses led to no
- 168 clinical intervention. Epidemiological data collection was previously performed as part of routine
- surveillance and infection prevention measures and hence constituted a non-research infection
- 170 control surveillance activity. Institutional review board exemption was granted by the SingHealth
- 171 Centralised Institutional Review Board (Reference number 2017-2576).
- 172 DNA extraction, WGS and sequence data analysis
- 173 Details of DNA extraction and WGS methods are in appendix 1 (p4). Methods used for
- sequence data analysis, including sequence read quality control, genome assembly, variant

- calling, genome relatedness analysis, phylogenetic analysis, antibiotic resistance gene analysis.
- 176 mating type loci analysis, chromosomal rearrangement analysis, in silico short tandem repeat
- 177 (STR) analysis, and divergence time estimation are available in appendix 1 (pp 4-7). Quality
- 178 statistics for the sequence data and genome assemblies generated in this study are
- summarized in appendix 2. In addition to the new sequence data generated in this study, 4,475
- publicly available genomes were initially included, of which 3,651 passed quality control and
- were included in downstream analysis. The list of publicly available genomes included, and their
- 182 quality statistics are in appendix 3.

Machine-learning models for detecting potential new clade

- 184 Current methods of clade determination rely on phylogenetic analysis or STR genotyping, the
- interpretation of which can be challenging, resulting in clade assignments that may be uncertain,
- as evidenced by the previous report on Isolate C, which was labeled as part of the Clade IV
- phylogenetic cluster²¹. There is currently no established threshold for SNP distance to flag an
- unusual *C. auris* genome as a potential new clade. To address this, we implemented a
- 189 Bayesian logistic regression model to determine whether a pair of genomes are from the same
- 190 clade based on SNP distances and previously reported clades. This threshold was then used to
- determine the relationship between genomes (an edge links genomes from the same clade) in a
- 192 graph, which captured clusters (connected components) representing existing and potential new
- 193 clades. We implemented the model using 3,651 publicly available whole-genome sequences,
- and the Clade VI whole-genome sequences generated in this study (appendix 3). 1,132 (31.0%)
- of the publicly available sequence data had previously reported clade information. All WGS data
- 196 were grouped into 19 quarterly datasets based on their date of public release (2019 June
- 197 2023). The number of clusters in the graph captured the number of clades present at each time
- 198 point. Detailed methods regarding the algorithm and model evaluation are in appendix 1(pp 8-
- 199 11).

203204

205

206

207

208

209210

183

200 Role of the funding source

- The funders of the study had no role in study design, data collection, data analysis, data
- interpretation, or writing of the report.

Results

All three Clade VI isolates (A, B, C) were phenotypically identified to be *C. auris*. Details for phenotypic identification results are in appendix 1 (p13). The colony morphology of all Clade VI isolates and the lactophenol cotton blue slide mount of isolate A at 600× magnification are in appendix 1 (p16). Antifungal susceptibility testing results are in **Table 1**. Further results and discussions on antifungal resistance testing are in appendix 1 (pp 22-24).

The index isolate from Patient A, isolate A (LIMS ID F3485, Biosample SAMN36753178) was cultured from a combined screening swab (nasal, axillae, and groin) in April 2023. The

cultured from a combined screening swab (nasal, axillae, and groin) in April 2023. The screening swab was taken within 24 hours of Patient A's admission as part of a *C. auris* active

- 213 surveillance program in the hospital. Patient A received treatment in the Department of Internal
- 214 Medicine and reported no travel history in the preceding two years. Since *C. auris* is not known
- to be endemic in Singapore, epidemiological, microbiological, and molecular investigations were
- initiated. Retrospective analysis of our laboratory's archived *C. auris* isolates found two
- additional isolates (B and C) to be similarly genetically distant to the five known clades, out of 43
- isolates analyzed. Isolate B (LIMS ID F1580, Biosample SAMN36753179) was cultured from an

intraoperative tissue specimen from Patient B, in April 2022. Patient B received treatment in the orthopedic unit and reported no recent travel history in the preceding two months, but had outpatient visits at hospitals in Indonesia in 2021. Isolate C (LIMS ID F0083, Biosample SAMN36753180) was cultured from the positive blood culture of Patient C in January 2018. Patient C was admitted directly from Bangladesh and the blood culture that was taken within 48 hours of admission grew *C. auris*. Isolate C was previously sequenced in 2019 and is one of the ten publicly available *C. auris* genomes submitted from Singapore (SRR10102336)²¹.

Extensive epidemiological investigations determined that Patients A, B, and C were separated spatially and temporally, with no overlap in physical space, clinical unit, and care facilities utilization in the large 1700-bed tertiary hospital. In accordance with the hospital's infection prevention policy, every positive case of *C. auris* triggered epidemiological investigations and contact tracing. All inpatients who shared the same ward or room with the positive cases were defined as contacts and they were screened for *C. auris* colonization as part of the infection prevention investigations. A total of 68 contacts were identified for Patients A and B. Patient C was isolated on admission and had no known contacts. None of the contacts screened positive for *C. auris* by routine diagnostic *C. auris* in-house validated PCR test or cultures. Furthermore, a total of 51 environmental samples were cultured to look for *C. auris* during the investigations, none of which yielded *C. auris*.

All three Clade VI *C. auris* isolates were whole-genome sequenced using two sequencing platforms: Illumina (short-read technology) and Oxford Nanopore (long-read technology), to obtain high-quality hybrid assemblies of the genomes. *De novo* hybrid genome assembly of the *C. auris* genomes was performed for the Singapore Clade VI isolates, and each consisted of eight to nine contigs, corresponding to near-complete genomes. The total assembly size was 12-4 to 12-5 Mbp. Quality statistics for Clade VI isolate sequence data and assemblies are available in appendix 2.

A comprehensive genome relatedness analysis using 3,651 *C. auris* WGS data in the NCBI database and sequence data generated in this study was performed (appendix 3). The final dataset included a total of 3,654 whole-genome sequences after quality control checks (appendix 1 p5), and >6.6 million genome pairs were analyzed. We found six distinct genetic clusters in this large-scale analysis. One additional *C. auris* genome (SRR24877249), independently submitted from Bangladesh, was found to belong to the same cluster as the Singaporean Clade VI isolates.

Since complete chromosomal sequences allow us to perform both whole genome phylogenetic and chromosomal rearrangement analyses, 14 representative genomes from known clades (I-V) with complete sequences of chromosomes were selected for in-depth downstream analysis. Phylogenetic analysis of the Clade VI genomes with these representative genomes showed that the Clade VI genomes were genetically distinct from the five known clades (**Figure 1A**). The four newly assembled Clade VI genomes clustered together in the new clade, which was more closely related to Clade IV but differed from all five known clades by at least 36,000 SNPs. The SNP distances between clades are shown in **Figure 1B**. The number of SNP differences within each clade is in appendix 1 (p17). *In silico* STR analysis was performed based on a previously published scheme, and the topology of the dendrogram also demonstrated clustering of Clade VI isolates based on STR profiles, congruent with the observation of a sixth clade using WGS ^{22,23} (appendix 1 p18). Additional Bayesian phylogenetic analysis suggests that the estimated divergence time of Clade VI from the most closely related Clade IV was at 4831 BCE (HPD 272·4 – 311·6 years ago). Details of the molecular clock analysis are in appendix 1 (p19).

We further investigated whether the Clade VI isolates have clade-specific features that distinguish them from their closest relatives in Clade IV. Previous studies observed clade-specific chromosomal rearrangements in *C. auris*^{24,25}. We reconstructed complete genomes to investigate if similar clade-specific large chromosomal rearrangements exist in the Singaporean Clade VI isolates (**Figure 2** and appendix 1 p20). Compared to Clade IV, an inversion in chromosome 5 was not observed in the Singaporean Clade VI genomes relative to Clade I. Furthermore, even though the new Clade VI isolates were most closely related to Clade IV, we found that they were of opposite mating types (**Figure 1C**). Clade IV isolates carry the *MTLa* allele at the *MAT* locus²⁴, while all Clade VI isolates belong to mating type α with amino acid identity of homologs above 95% based on BLAST matches (appendix 1 p21).

Given the marked difference among whole genomes of *C. auris* from different clades, we exploited the SNP distances between the genomes to develop a system to monitor and alert for the emergence of potentially new clades. Using publicly available WGS data of 3,651 isolates and the three representative genomes from Clade VI, with a final dataset of >6.6 million genome pairs, we simulated the detection of Clade V and Clade VI at two time points, when the WGS data became available (**Figure 3**). Although the amount of WGS data increased from 554 genomes in 2019 Q1 to 3,654 genomes in 2023 Q3 (appendix 1 pp25-26), the SNP distance thresholds inferred by the Bayesian logistic regression model were consistently between 19,000 – 23,000 SNPs across the time points (**Figure 3A**). The model detected the emergence of Clades V (2019 Q3) and VI (2023 Q2) as it monitored the SNP distance amongst the genomes over time (**Figure 3B**). As an illustrative example, in 2023 Q3, there were six connected components and each component consisted of genomes from the same clade (**Figure 3C**). Detailed results on the automatic detection of new clades can be found in appendix 1 pp 25-26.

Discussion

We report the discovery of the sixth major clade of *C. auris*, which includes three epidemiologically unlinked isolates detected in Singapore, and one publicly available WGS data of an isolate reported from Bangladesh (SRR24877249). This conclusion is based upon extensive genomic analysis demonstrating the clustering of these four isolates, and large genetic divergence from the five known clades. We obtained high-quality hybrid genome assemblies of the Singaporean Clade VI isolates, and analyzed these genomes together with 3,651 publicly available *C. auris* whole-genome sequences.

Although the samples that yielded these isolates were collected in Singapore and Bangladesh, the Clade VI isolates were most closely related to representatives of Clade IV (divergence of ~36,000 SNPs), which were mostly from South America. The genomic distance observed between Clades IV and VI is greater than that observed between Clades I and III (~35,000 SNPs). Within Clade VI, the three Singaporean isolates were distinct in at least 70 SNPs. This within-clade difference is similar to what was previously reported among Iranian Clade V isolates, which were cultured from patients with community-onset otomycosis 15. The independent detection of Clade VI isolates from Singapore and Bangladesh suggests that Clade VI strains might have been circulating undetected in Southeast Asia and South Asia. Given the estimated divergence time from Clade IV, we speculate that there may exist an endemic zone or a special ecological habitat for Clade VI *C. auris* in the Indomalaya biogeographic realm. Further discussion on the divergence time is available in appendix 1 p25.

The Clade VI isolates in Singapore were distinct from their closest relatives in Clade IV based on phenotypic investigations and genomic analysis. Firstly, the susceptibility to antifungals, and

lack of known AMR resistance-conferring mutations in the Clade VI isolates (**Table 1** and appendix 1 p22-24) are unlike that of Clade IV, where approximately half of the isolates are resistant to fluconazole^{10,14,26,27}. Secondly, Clade VI isolates lack an inversion observed in Clade IV (**Figure 2** and appendix p20). Thirdly, Clade VI isolates carry the $MTL\alpha$ allele, a mating-type allele opposite to the $MTL\alpha$ observed in Clade IV. As isolates of opposite mating types are yet to be found within the same clade, taken together with other findings presented in this study, the Clade VI isolates are likely representatives of a new major clade rather than a sub-lineage of an existing clade. Further discussion on mating type can be found in appendix 1 p25.

Unlike the five known *C. auris* clades that are named after their geographic location, these Clade VI isolates detected in Singapore have no known specific geographic associations yet. Due to the retrospective nature of this study, extensive travel history could not be obtained from the patients. We postulate that isolate C was related to Bangladesh geographically, as Patient C was airlifted from Bangladesh to Singapore and isolate C was grown from the blood culture taken within 48 hours of his admission. The independent detection of another Clade VI isolate in Bangladesh (SRR24877249, sample collected in 2021) suggests that Clade VI strains may be circulating undetected in Bangladesh, with the first documented Clade VI isolate being detected in Singapore (isolate C, F0083). Patient B was known to have epidemiological links to Indonesia and Singapore, but not to Bangladesh or South Asia. Patient A was not known to have left Singapore in the preceding two years and has no known epidemiological link to South Asia. The identification of more Clade VI isolates may help us to pinpoint a geographic origin for this emergent clade. Further discussion on the detection and containment of *C. auris* in Singapore is in appendix 1 p25.

While the origin of Clade VI cannot be resolved, the cryptic circulation of Clade VI C. auris in Southeast Asian and South Asian countries is evident because all four patients had epidemiological links to Bangladesh, Indonesia, and Singapore. Due to the paucity of *C. auris* data in the region, it is unclear whether Clade VI is widespread or expanding from its presumed endemic zone. Its potential for causing outbreaks also remains unknown. Clades I, III, and IV are known to cause prolonged outbreaks in healthcare settings^{3,6,14,27–31}. As a result, the acquisition of Clades I, III, and IV C. auris is often traced to healthcare settings. On the contrary, Clades II and V are not known to be healthcare-associated 10,15,32,33. Although the generally wildtype antifungal susceptibility profile of Clade VI resembles that of Clades II and V, two of the three Clade VI isolates were detected in invasive clinical infections (blood and intraoperative tissue). This is unlike Clades II and V, which are most commonly associated with communityonset otomycosis 10,15,32,33. As the virulence and outbreak potential of Clade VI *C. auris* is yet to be established, it is imperative to ensure its early detection and containment for the purpose of patient safety. Since we have yet to identify the source, the risk factor(s) for acquisition, and the specific geographical associations of Clade VI C. auris, active surveillance strategies and priorities may need to be reassessed by individual healthcare institutions, to balance possible emergent threat containment with optimal healthcare resource utilization.

The Clade VI isolates were detected as part of a microbial genomic surveillance program within a Singaporean academic medical center. Although laboratories are increasingly able to obtain microbial genome sequences, it is evident that ongoing, large-scale genomic analysis to provide relevant public health alerts continues to be challenging. We aimed to augment our ability to detect outlier genomes, such as the Clade VI genomes reported in this study, by demonstrating a proof-of-concept machine learning approach that can automatically identify outlier genomes (detection of Clades V and VI) for enhancing genomic surveillance (**Figure 3**). Further discussion on the results and limitations of this machine learning approach can be found in appendix 1 pp25-26.

This study has several limitations. Due to the retrospective nature of this study, full travel and exposure history could not be traced. The sample size of Clade VI isolates was small, and therefore the reported genomes may not be representative of the entire clade. The antifungal susceptibility test was not performed with a reference broth dilution method but was performed with Sensititre TM YeastOne TM plates. Stringent quality control of publicly available WGS data discarded 18.4% (824/4475) of available genome data, including isolate C's sequence (SRR10102336) reported from Singapore in 2019²¹. This significant data loss from suboptimal quality suggests that when applied in practice, our mathematical modelling approach to detect new clades will face additional challenges, and the framework presented in this study therefore represents a proof-of-concept that requires further evaluations and fine-tuning.

Worsening spread of *C. auris* has recently been reported in Europe and in the United States^{34–36}. It is evident that *C. auris* continues to be a threat to public health notwithstanding the resources available for surveillance and containment in high-income countries. Given the resource limitation in parts of Indomalaya, innovative solutions are necessary to augment regional microbial genomic surveillance. Cost-effective integration of existing routine infectious disease diagnostics with genomic surveillance at sentinel sites^{37–39}, together with effective sequence data analysis, are essential components for pandemic preparedness. Our study provides evidence for the discovery of the sixth major *C. auris* clade in Singapore and underscores the need to enhance genomic surveillance in strategic sentinel sites.

Figure legends

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410 411

412

413

414

415

416

417

418

419

420 421

422

423

424

425

426 427

428

429

430

431

432

433

434

435

436

437

438

Figure 1. (A) Genetic relationships among representative Candida auris genomes from five known clades and the newly identified sixth clade. Six distinct genetic clusters were observed, each consisting of genomes from the same clade. Genetic relationships were inferred using maximum-likelihood phylogenetic analysis, with 1,000 bootstrap replicates. The publicly available B8441 genome was used as a reference to identify small nucleotide polymorphisms (SNPs) in other isolates. Hybrid assemblies of the Singaporean C. auris isolates A (F3485), B (F1580), and C (F0083), were used in this analysis. An additional publicly available wholegenome sequence independently submitted from Bangladesh (SRR24877249) was found to belong to the same cluster as the Singaporean Clade VI isolates. The Clade VI genomes are labeled in blue bolded fonts. Yellow circle denotes the bootstrap value. The scale bar represents the mean number of nucleotide substitutions per site. (B) SNP difference among representative C. auris genomes. The numbers within each box indicate the number of SNP differences observed between genomes in distinct clades (in thousands). Isolates between different clades were divergent in at least 35,000 positions genome-wide (e.g. between Clades I and III). Clade VI genomes were divergent in at least 36,000 SNPs from all known clades (I-V). Purple boxes within the heatmap represent genomes that are divergent in ≤5,000 SNPs from each other. (C) Summary of mating type predictions for each clade, determined based on the MTLa/α alleles present at the MAT locus.

Figure 2. Chromosomal rearrangements in *Candida auris*. Chord diagrams showing translocations and inversions in representative genomes for clades II, III, IV, V, and VI, using CA-AM1 (Clade I) as a reference. Only rearrangement events of size >10,000bp are displayed. Based on whole-genome alignments, Clade VI has an inversion in the long arm of chromosome 1, which is also observed in the representative genomes from Clades II, III, IV, and V. We also identified a unique translocation event between chromosomes 2 and 4 in Clade VI. Representative isolate genomes used in this figure: Clade I, CA-AM1 (GCA_014673535); Clade II, B13463 (GCA_016495665); Clade III, A1 (GCA_014217455); Clade IV, B11245 (GCA_008275145); Clade V, B18474 (SRR13269545); Clade VI, isolate A (F3485).

Figure 3. Detection of potentially new Candida auris clades using a Bayesian analysis framework. (A) Line plot illustrates small nucleotide polymorphism (SNP) distance thresholds learned across time points using Bayesian logistic regression. The Y-axis represents the SNP distance between genome pairs. The pink dashed line represents the mode of the SNP distance threshold (d), and the shaded region represents the 95% high-density interval (HDI) bounded by d_{low} and d_{high} . The purple solid line marks d_{high} . When the SNP distance is greater than d_{high} , the input genome pair is predicted to be from different clades. The X-axis represents time in quarterly units, where C. auris whole genome sequence (WGS) data released within the same time period were added incrementally into the training dataset. (B) Line plot illustrates the number of connected components (Y-axis) detected over time (X-axis in quarterly units). The emergence of Clade V and Clade VI were detected by the rise in the number of connected components (CCs) (black arrows). (C) Graph visualization of the relationships between genomes in 2023 Q3. Each node represents a C. auris genome, and node color denotes clades. Each color represents genomes with known clade information. Gray nodes represent genomes without clade information in the literature. For ease of visualization, we subsampled the genomes in the components which contain more than 200 genomes. An edge links two nodes when $s < d_{high}$, indicating that the genomes are predicted to belong to the same clade. Six connected components were observed across 3,654 genomes.

Tables

Table 1. Minimum inhibitory concentration (MIC) values of Singapore Clade VI Candida auris isolates. Antifungal susceptibility testing was performed using the Sensititre[™] YeastOne[™] ITAMYUCC Plate (Thermo Scientific, Cleveland, OH, USA) according to the manufacturer's instructions, in a College of American Pathologists-accredited clinical laboratory. *5-Flucytosin MIC was determined using the Sensititre[™] YeastOne[™] YO10 Plate (International version) (Thermo Scientific, Cleveland, OH, USA). Isolates A and B exhibited wild-type MICs for all tested antifungals^{40,41}.

	Minimum inhibitory concentration (mg/L) of						
	Isolate A (F3485)	Isolate B (F1580)	Isolate C (F0083)				
Anidulafungin	0.12	0.12	0.12				
Micafungin	0.12	0.06	0.06				
Caspofungin	0.06	0.06 0.03					
5-Flucytosine*	≤ 0.06 ≤ 0.06		≤ 0.06				
Isavuconazole	0.03	≤ 0.008	0.06				
Posaconazole	0.03	≤ 0.008	0.06				
Voriconazole	0.03	≤ 0.008	0.06				
Itraconazole	0.06	0.03	0.12				
Fluconazole	2.00	1.00	4.00				
Amphotericin B	1.00 0.50		2.00				

Contributors

449

- 450 CS and KK conceptualized the study and CS, KK, and CT prepared the draft manuscript. CS,
- 451 KK, CT, KML, and MGT performed the literature search. KML, CT, and NN contributed to the
- 452 conceptualization and design of the study. MGT, ALT, and YET contributed isolates for analyses
- and provided expert advice on clinical mycology. CS, KK, KML, PB, SSG, PR, BS and JJKC
- 454 contributed to the data acquisition and analysis process. KSC and LO contributed samples for
- analysis and provided expert advice on clinical molecular microbiology. LCL, MLL, BBSI, MKA,
- 456 YY, JXYS, and IV provided epidemiological data and expert infection control and prevention
- 457 advice. BC and LW provided specialist infectious disease inputs and clinical data. JFM provided
- 458 expert advice and supported STR and phylogenetic timing analysis. BS performed STR and
- 459 phylogenetic timing analysis. BHT and THK critically evaluated the clinical, microbiological, and
- 460 epidemiological data and analysis. NN critically evaluated the genomic data analysis. All authors
- 461 contributed to the manuscript, and edited and reviewed the final manuscript. CS and KK
- 462 accessed and verified the raw data. CS and KK contributed equally to this work. All authors had
- 463 full access to all the data in the study and had final responsibility for the decision to submit for
- 464 publication.

465

Data sharing

- The code used to perform WGS analyses and train machine-learning models in this study is
- 467 available at https://github.com/CSB5/Candida_auris_CladeVI. Reads and genome assemblies
- 468 from this study have been deposited in the National Centre for Biotechnology Information
- 469 (NCBI) Sequence Read Archive (SRA) database (https://www.ncbi.nlm.nih.gov/sra) under
- 470 BioProject accession number PRJNA1000034.

471 Declaration of interests

472 All authors declare no competing interests.

473 Supplementary Material

- 474 Supplementary Appendix 1
- 475 Supplementary Appendix 2
- 476 Supplementary Appendix 3

477 Acknowledgements

- 478 This work was supported by the NCRS Duke-NUS Academic Medical Center Academic Clinical
- 479 Program grant (09/FY2022/P1/17-A32, GRDUKP003401), the Genedant-GIS Innovation
- Program grant, resources from the Genome Institute of Singapore (GIS), and resources from
- 481 Singapore General Hospital (SGH). Karrie K. K. Ko is supported by the Singapore National
- 482 Medical Research Council (NMRC) research training fellowship (MOH-FLWSHP19may-0005).
- 483 The work was supported in part through computational resources (Sockeye) and services
- 484 provided by Advanced Research Computing at the University of British Columbia, Vancouver,
- 485 Canada. We thank members of the Diagnostic Bacteriology Laboratory and the Molecular
- 486 Laboratory, SGH, for their technical assistance. We thank members of the Department of
- Infection Prevention and Epidemiology, SGH, for their assistance with epidemiologic data. We
- 488 thank the Department of Infectious Diseases, SGH, for their assistance with clinical data. We

- thank members of the Laboratory of Metagenomic Technologies and Microbial Systems, GIS,
- 490 for their helpful comments on genomic analysis.

491 References


- 492 1 Chowdhary A, Jain K, Chauhan N. *Candida auris* Genetics and Emergence. *Annu Rev* 493 *Microbiol* 2023; published online July 5. DOI:10.1146/annurev-micro-032521-015858.
- 494 2 Morales-López SE, Parra-Giraldo CM, Ceballos-Garzón A, *et al.* Invasive Infections with 495 Multidrug-Resistant Yeast *Candida auris*, Colombia. *Emerg Infect Dis* 2017; **23**: 162–4.
- 496 3 Ruiz-Gaitán A, Moret AM, Tasias-Pitarch M, *et al.* An outbreak due to *Candida auris* with prolonged colonisation and candidaemia in a tertiary care European hospital. *Mycoses* 2018; **61**: 498–505.
- 499 4 Adams E, Quinn M, Tsay S, *et al. Candida auris* in Healthcare Facilities, New York, USA, 2013-2017. *Emerg Infect Dis* 2018; **24**: 1816–24.
- 501 5 Eyre DW, Sheppard AE, Madder H, *et al.* A *Candida auris* Outbreak and Its Control in an Intensive Care Setting. *N Engl J Med* 2018; **379**: 1322–31.
- 503 6 Schelenz S, Hagen F, Rhodes JL, *et al.* First hospital outbreak of the globally emerging Candida auris in a European hospital. *Antimicrob Resist Infect Control* 2016; **5**: 35.
- 505 7 Chowdhary A, Sharma C, Duggal S, *et al.* New clonal strain of *Candida auris*, Delhi, India. *Emerg Infect Dis* 2013; **19**: 1670–3.
- Theodoropoulos NM, Bolstorff B, Bozorgzadeh A, *et al. Candida auris* outbreak involving liver transplant recipients in a surgical intensive care unit. *Am J Transplant* 2020; **20**: 3673–9.
- 510 9 Calvo B, Melo ASA, Perozo-Mena A, *et al.* First report of *Candida auris* in America: Clinical and microbiological aspects of 18 episodes of candidemia. *J Infect* 2016; **73**: 369–74.
- 512 10 Chow NA, de Groot T, Badali H, Abastabar M, Chiller TM, Meis JF. Potential Fifth Clade of Candida auris, Iran, 2018. *Emerg Infect Dis* 2019; **25**: 1780–1.
- 514 11 Welsh RM, Bentz ML, Shams A, *et al.* Survival, Persistence, and Isolation of the Emerging Multidrug-Resistant Pathogenic Yeast *Candida auris* on a Plastic Health Care Surface. *J Clin Microbiol* 2017; **55**: 2996–3005.
- 517 12 Fisher MC, Denning DW. The WHO fungal priority pathogens list as a game-changer. *Nat Rev Microbiol* 2023; **21**: 211–2.
- 519 13 Centers for Disease Control and Prevention (U.S.) National Center for Emerging Zoonotic 520 and Infectious Diseases (U.S.). Division of Healthcare Quality Promotion. Antibiotic 521 Resistance Coordination and Strategy Unit. Antibiotic resistance threats in the United 522 States, 2019. DOI:10.15620/cdc:82532.
- 523 14 Lockhart SR, Etienne KA, Vallabhaneni S, *et al.* Simultaneous Emergence of Multidrug-524 Resistant *Candida auris* on 3 Continents Confirmed by Whole-Genome Sequencing and

525 Epidemiological Analyses. *Clin Infect Dis* 2017; **64**: 134–40.

- 526 15 Spruijtenburg B, Badali H, Abastabar M, *et al.* Confirmation of fifth *Candida auris* clade by whole genome sequencing. *Emerg Microbes Infect* 2022; **11**: 2405–11.
- 528 16 Abastabar M, Haghani I, Ahangarkani F, *et al. Candida auris* otomycosis in Iran and review of recent literature. *Mycoses* 2019; **62**: 101–5.
- 530 17 Jeffery-Smith A, Taori SK, Schelenz S, *et al. Candida auris*: a Review of the Literature. *Clin Microbiol Rev* 2018; **31**. DOI:10.1128/CMR.00029-17.
- 532 18 Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. *Candida auris* sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. *Microbiol Immunol* 2009; **53**: 41–4.
- 535 19 Rhodes J, Fisher MC. Global epidemiology of emerging *Candida auris*. *Curr Opin Microbiol* 2019; **52**: 84–9.
- Iguchi S, Itakura Y, Yoshida A, *et al. Candida auris*: A pathogen difficult to identify, treat, and eradicate and its characteristics in Japanese strains. *J Infect Chemother* 2019; **25**: 743–9.
- Tan YE, Teo JQ-M, Rahman NBA, et al. Candida auris in Singapore: Genomic
 epidemiology, antifungal drug resistance, and identification using the updated 8.01
 VITEK 2 system. Int J Antimicrob Agents 2019; 54: 709–15.
- 543 22 de Groot T, Spruijtenburg B, Parnell LA, Chow NA, Meis JF. Optimization and Validation of 544 *Candida auris* Short Tandem Repeat Analysis. *Microbiol Spectr* 2022; **10**: e0264522.
- de Groot T, Puts Y, Berrio I, Chowdhary A, Meis JF. Development of *Candida auris* Short
 Tandem Repeat Typing and Its Application to a Global Collection of Isolates. *MBio* 2020;
 11. DOI:10.1128/mBio.02971-19.
- 548 24 Muñoz JF, Gade L, Chow NA, *et al.* Genomic insights into multidrug-resistance, mating and virulence in *Candida auris* and related emerging species. *Nat Commun* 2018; **9**: 5346.
- 550 25 Muñoz JF, Welsh RM, Shea T, et al. Clade-specific chromosomal rearrangements and loss
 551 of subtelomeric adhesins in *Candida auris*. *Genetics* 2021; 218: iyab029.
 552 DOI:10.1093/genetics/iyab029.
- 553 26 Chowdhary A, Prakash A, Sharma C, *et al.* A multicentre study of antifungal susceptibility 554 patterns among 350 *Candida auris* isolates (2009-17) in India: role of the ERG11 and FKS1 555 genes in azole and echinocandin resistance. *J Antimicrob Chemother* 2018; **73**: 891–9.
- Chow NA, Muñoz JF, Gade L, *et al.* Tracing the Evolutionary History and Global Expansion of *Candida auris* Using Population Genomic Analyses. *MBio* 2020; **11**.
 DOI:10.1128/mBio.03364-19.
- 559 28 Mulet Bayona JV, Tormo Palop N, Salvador García C, *et al.* Characteristics and 560 Management of Candidaemia Episodes in an Established *Candida auris* Outbreak. 561 *Antibiotics (Basel)* 2020; **9**. DOI:10.3390/antibiotics9090558.
- 562 29 Salah H, Sundararaju S, Dalil L, *et al.* Genomic Epidemiology of *Candida auris* in Qatar 563 Reveals Hospital Transmission Dynamics and a South Asian Origin. *J Fungi (Basel)* 2021;

7. DOI:10.3390/jof7030240.

- 565 30 Chow NA, Gade L, Tsay SV, *et al.* Multiple introductions and subsequent transmission of multidrug-resistant *Candida auris* in the USA: a molecular epidemiological survey. *Lancet Infect Dis* 2018; **18**: 1377–84.
- 568 31 Ben Abid F, Salah H, Sundararaju S, *et al.* Molecular characterization of *Candida auris* 569 outbreak isolates in Qatar from patients with COVID-19 reveals the emergence of isolates 570 resistant to three classes of antifungal drugs. *Clin Microbiol Infect* 2023; published online 571 April 26. DOI:10.1016/j.cmi.2023.04.025.
- 572 32 Sekizuka T, Iguchi S, Umeyama T, *et al.* Clade II *Candida auris* possess genomic structural variations related to an ancestral strain. *PLoS One* 2019; **14**: e0223433.
- 574 33 Kwon YJ, Shin JH, Byun SA, *et al. Candida auris* Clinical Isolates from South Korea: Identification, Antifungal Susceptibility, and Genotyping. *J Clin Microbiol* 2019; **57**. DOI:10.1128/JCM.01624-18.
- 577 34 Lyman M, Forsberg K, Sexton DJ, *et al.* Worsening Spread of *Candida auris* in the United States, 2019 to 2021. *Ann Intern Med* 2023; **176**: 489–95.
- 579 35 Kilburn S, Innes G, Quinn M, *et al.* Antifungal Resistance Trends of *Candida auris* Clinical Isolates in New York and New Jersey from 2016 to 2020. *Antimicrob Agents Chemother* 2022; **66**: e0224221.
- 582 36 Kohlenberg A, Monnet DL, Plachouras D, *Candida auris* survey collaborative group.
 583 Increasing number of cases and outbreaks caused by Candida auris in the EU/EEA, 2020 to 2021. *Euro Surveill* 2022; **27**. DOI:10.2807/1560-7917.ES.2022.27.46.2200846.
- 585 37 Ko KKK, Chu JJK, Lim KM, *et al.* Clonal serotype 1c multidrug-resistant *Shigella flexneri* detected in multiple institutions by sentinel-site sequencing. *Front Med* 2022; **9**: 964640.
- 587 38 Yingtaweesittikul H, Ko K, Rahman NA, Tan SYL, Nagarajan N, Suphavilai C. CalmBelt: rapid SARS-CoV-2 genome characterisation for outbreak tracking. *Front Med 2021*; 8: 790662. doi: 10.3389/fmed.2021.790662.
- 590 39 Ko KKK, Chng KR, Nagarajan N. Metagenomics-enabled microbial surveillance. *Nat Microbiol* 2022; **7**: 486–96.
- 592 40 Clinical and Laboratory Standard Institutes. Clinical and Laboratory Standard Institutes 593 (CLSI). Epidemiological Cutoff Values for Antifungal Susceptibility Testing, 4th Edition. 594 CLSI Supplement M57S. USA,2022. USA: Clinical and Laboratory Standard Institutes.
- 595 41 Antifungal Susceptibility Testing and Interpretation. 2023; published online April 5. 596 https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html (accessed July 01, 2023).



Clade	I	II	III	IV	v	VI
Mating type locus	MTLa	MTLα	MTLα	MTLa	MTLa	MTLα

